|
1. Biologie
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.3 Dép., diag. & prono. - Industriels
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
We need more answers about immunotherapy for the elderly [STAT]
|
|
|
|
|
|
As
we age, our immune systems change, presenting us with new challenges.
Access to promising, life-extending cancer treatments like immunotherapy
should not be among these challenges simply because older patients have
not been included in clinical trials.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.6.16 ESMO - Appareil digestif
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
As I predicted, the exploitation of desperate patients using right-to-try begins [Respectful Insolence]
|
|
|
|
|
|
Poor
Dr. Gottlieb. He thought that right-to-try was about expanding access
to promising therapeutic agents and not about emasculating the FDA.
Well, Sen. Johnson sure set him straight, and because Sen. Johnson set
Dr. Gottlieb straight I highly doubt that Dr. Gottlieb will be too
enthusiastic about being too aggressive going after companies like
BrainStorm looking to profit (whether “modestly” or otherwise) from
right-to-try.
|
|
|
|
|
|
|
|
6.12 Ethique
|
|
|
|
6.6 Publications
|
|
|
|
|
6.9 Controverses
|
|
|